FDA Adverse Event Injury Summary report: N

SYNVISC

MDR report key: 204450 · Received December 23, 1998

Report

Report Number
1310337-1998-00007
Event Type
Injury
Date Received
December 23, 1998
Date of Event
May 1, 1998
Report Date
May 8, 1998
Manufacturer
BIOMATRIX, INC.
Product Code
MOZ
Adverse Event
Yes
Report Source
Distributor report
Reporter Location
NY, US
Reporter Occupation
PHYSICIAN

Narratives

Description of Event or Problem · 1

INFO HAS BEEN RECEIVED FROM A PHYSICIAN AND FROM MEDICAL RECORDS FORWARDED BY THE MFR REGARDING A 42-YEAR-OLD FEMALE WHO RECEIVED THREE RIGHT KNEE INJECTIONS OF SYNVISC (3/25/1998, 4/2/1998 AND 4/8/1998) IN THE TREATMENT OF OSTEOARTHRITIS. CONCOMITANT THERAPY INCLUDED ELAVIL (AMITRIPTYLINE PAMOATE), LORCET (ACETAMINOPHEN & HYDROCODONE BITARTRATE) AND KETOPROFEN. ADDITIONAL MEDICAL HISTORY INCLUDED A RIGHT KNEE MAQUET PROCEDRE (1988) WITH SUBSEQUENT DEVELOPMENT OF REFLEX SYMPATHETIC DYSTROPHY (1991); ARTHROSCOPIC SURGERY FOR A RIGHT PARTIAL MENISECTOMY; SURGICAL GRAFTING OF THE TIBIAL CREST FROM A PELVIC GRAFT (12/1993); CHRONIC LOW BACK PAIN TREATED WITH STERIOD INJECTIONS IN L1 & L2 AND THE SUBSEQUENT DEVELOPMENT OF OSTEOMYELITIS OF L1-L2. THE PT EXPERIENCED ACUTE INTENSE RIGHT KNEE PAIN AND SWELLING 5 WEEKS FOLLOWING THE THIRD INJECTION. ON 4/29/1998 SHE WAS EVALUATED BY HER PHYSICIAN WHO NOTED SWELLING BUT NO SIGNS OF SYNOVITIS. AN X-RAY WAS PERFORMED AND REVEALED SOME CALCIFICATION AROUND THE MEDIAL COMPARTMENT. HOWEVER, ON 5/1/1998 THE PAIN AND SWELLING HAD INCREASED AND THE PHYSICIAN NOTED SOME REDNESS OVER THE LATERAL PATELLA REINACULUM. AN ARTHROCENTESIS WAS PERFORMED. THE CULTURE AND GRAM STAIN WERE NEGATIVE FOR AN INFECTION. THE PATHOLOGY REPORT INDICATED A "SYNOVIUM REACTION" TO A FOREIGN BODY ("BELIEVED TO BE SYNVISC") WHICH WAS DESCRIBED AS A "GIANT CELL REACTION" (GRANULOMA). DISTRIBUTOR'S COMMENTS: THIS REPORT IS BEING SUBMITTED AT THE DISTRIBUTOR'S REQUEST, AS THEY HAVE RECENTLY DETERMINED THAT THEY HAD A REPORTING RESPONSIBLITY DURING THE TIME PERIOD THAT THIS EVENT OCCURRED. THE MFR HAD AN ESTABLISHED MDR REVIEW AND CLOSEOUT PROCESS IN PLACE, AND THIS WAS FOLLOWED ACCORDING TO THE BUSINESS ARRANGEMENT BETWEEN THE TWO PARTIES. IT WAS NOT DEEMED REPORTABLE ACCORDING TO MDR REGULATIONS. THE MFR HAS INCLUDED THIS CASE IN THE SAFETY SUMMARY OF THE PMA ANNUAL REPORT FOR THIS DEVICE MEDICAL PRODUCT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 SYNVISC HYLAN G-F 20 MOZ BIOMATRIX, INC. * *

Patients

Seq Age Sex Outcome Treatment
1 42 YR Hospitalization BILARTRATE 10 MG AS NEEDED FOR PAIN).| ELAVIL (AMITROCIPTYLINE PAMOATE) 75 MG AT BEDTIME,| LORCET (ACETAMINOPHEN 650 MG AND HYDROCODONE| KETOPROFEN 75 MG TWICE DAILY,